Brief: Xintela Stem Cell Product Assessed As Safe In Study

Xintela AB

13/10/2023 14:27

Oct 13 (Reuters) - Xintela AB  XINT.ST :
    * XINTELA’S STEM CELL PRODUCT, XSTEM, HAS BEEN ASSESSED AS
SAFE AT
ALL DOSE LEVELS IN KNEE OSTEOARTHRITIS CLINICAL STUDY

Source text for Eikon:  ID:nMFN7TgC5y 
Further company coverage:  XINT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))